Phase II trial reports 71% graft-versus-host disease-free survival in myelofibrosis patients after transplantation, indicating effective use of ruxolitinib.
Key Points
Ruxolitinib administration resulted in a 71% one-year graft-versus-host disease-free survival for patients with myelofibrosis after transplantation.
During a median follow-up of 27 months, the overall survival rate was 82% with notable low rates of severe acute graft-versus-host disease.
This was a phase II, multicenter clinical trial involving 43 participants receiving reduced-intensity hematopoietic cell transplantation.
The findings highlight the safety and tolerability of ruxolitinib, suggesting it may improve survival outcomes and reduce the risk of complications post-transplant.